A detailed history of Group One Trading, L.P. transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 74,984 shares of ABCL stock, worth $206,955. This represents 0.01% of its overall portfolio holdings.

Number of Shares
74,984
Previous 18,975 295.17%
Holding current value
$206,955
Previous $56,000 246.43%
% of portfolio
0.01%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.39 - $3.49 $133,861 - $195,471
56,009 Added 295.17%
74,984 $194,000
Q2 2024

Aug 14, 2024

SELL
$2.73 - $4.73 $37,674 - $65,274
-13,800 Reduced 42.11%
18,975 $56,000
Q1 2024

May 10, 2024

BUY
$4.29 - $5.97 $47,623 - $66,272
11,101 Added 51.22%
32,775 $148,000
Q4 2023

Feb 14, 2024

SELL
$3.91 - $5.93 $146,429 - $222,078
-37,450 Reduced 63.34%
21,674 $123,000
Q3 2023

Nov 09, 2023

BUY
$4.6 - $7.95 $257,199 - $444,508
55,913 Added 1741.3%
59,124 $271,000
Q2 2023

Aug 09, 2023

SELL
$5.66 - $7.59 $76,036 - $101,964
-13,434 Reduced 80.71%
3,211 $20,000
Q1 2023

May 12, 2023

SELL
$7.31 - $11.18 $295,645 - $452,163
-40,444 Reduced 70.84%
16,645 $125,000
Q4 2022

Feb 09, 2023

BUY
$9.48 - $14.52 $433,965 - $664,682
45,777 Added 404.68%
57,089 $578,000
Q3 2022

Nov 09, 2022

SELL
$9.2 - $13.68 $570,179 - $847,831
-61,976 Reduced 84.57%
11,312 $112,000
Q2 2022

Aug 11, 2022

BUY
$5.72 - $10.65 $419,207 - $780,517
73,288 New
73,288 $781,000
Q1 2022

May 12, 2022

SELL
$7.46 - $14.14 $630,601 - $1.2 Million
-84,531 Closed
0 $0
Q4 2021

Feb 11, 2022

BUY
$12.99 - $17.73 $1.1 Million - $1.5 Million
84,531 New
84,531 $1.21 Million
Q3 2021

Nov 12, 2021

SELL
$14.85 - $21.34 $285,446 - $410,197
-19,222 Closed
0 $0
Q2 2021

Aug 10, 2021

BUY
$20.19 - $34.17 $388,092 - $656,815
19,222 New
19,222 $423,000

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $787M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track Group One Trading, L.P. Portfolio

Follow Group One Trading, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.